Targeted Alpha Therapy (TAT)
The emerging TAT market represents a paradigm shift in oncology. High-energy, short-range alpha particles deliver devastating double-strand DNA breaks directly to metastatic cancer cells while sparing healthy tissue. The primary bottleneck is the severe scarcity of the necessary radioisotopes.
The Supply Chain Crisis
The most promising alpha emitter, Actinium-225 (225Ac), has a half-life of 10 days. Currently, the global supply of high-purity 225Ac is approximately 2 curies per year—enough to treat perhaps a few thousand patients globally.
As clinical trials (like those for metastatic prostate cancer and neuroendocrine tumors) progress toward FDA approval, clinical demand is projected to scale to over 100 curies per year by 2028.
"We are observing a scramble for medical isotopes that mirrors the semiconductor lithography supply constraints of the early 2020s. Capital is abundant; atoms are scarce."
Production requires sophisticated cyclotrons or linear accelerators bombarding Radium-226 targets. The high capital expenditure and regulatory hurdles create massive barriers to entry.
Key Alpha Emitters
Actinium-225
10-day half-life. The "gold standard" for TAT. Produces 4 net alpha particles in its decay chain.
Lead-212
10.6-hour half-life. Requires generator systems for hospital-level extraction.
Thorium-227
18.7-day half-life. Favorable logistics but different chelator requirements.
Investment Thesis & Asset Allocation
Alpha generation in this sector requires identifying the bottleneck constraint. Currently, equity markets are pricing in the success of the clinical pipelines (pharmaceutical companies) while ignoring the inevitable manufacturing cliff.
Our strategy focuses on upstream targets: cyclotron manufacturers, target irradiation facility operators, specialized radiochemistry contract development and manufacturing organizations (CDMOs), and the logistics providers capable of managing just-in-time delivery of sub-10-day half-life materials globally.